Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-03 4:08 pm Purchase |
2024-12-27 | 13G | RAPT Therapeutics, Inc. RAPT |
TCG Crossover GP II, LLC | 13,193,110 9.990% |
13,193,110 (New Position) |
Filing History |
| 2024-12-03 4:34 pm Purchase |
2024-11-26 | 13G | Cidara Therapeutics, Inc. CDTX |
TCG Crossover GP II, LLC | 1,005,901 9.200% |
1,005,901 (New Position) |
Filing History |
| 2024-11-22 4:41 pm Purchase |
2024-11-15 | 13G | Dianthus Therapeutics, Inc. DNTH |
TCG Crossover GP II, LLC | 1,501,624 5.100% |
1,501,624 (New Position) |
Filing History |
| 2024-11-20 4:24 pm Purchase |
2024-11-13 | 13G | Tango Therapeutics, Inc. TNGX |
TCG Crossover GP II, LLC | 10,500,612 9.800% |
10,500,612 (New Position) |
Filing History |
| 2024-11-13 4:27 pm Sale |
2024-09-30 | 13G | Mineralys Therapeutics, Inc. MLYS |
TCG Crossover GP II, LLC | 2,470,265 5.000% |
-714,920 (-22.45%) |
Filing History |
| 2024-11-13 4:21 pm Sale |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
TCG Crossover GP II, LLC | 2,761,861 4.900% |
-1,607,067 (-36.78%) |
Filing History |
| 2024-11-07 4:27 pm Purchase |
2024-10-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
TCG Crossover GP II, LLC | 3,572,335 5.200% |
3,572,335 (New Position) |
Filing History |
| 2024-09-27 4:52 pm Purchase |
2024-09-18 | 13G | Third Harmonic Bio, Inc. THRD |
TCG Crossover GP II, LLC | 2,415,000 5.900% |
2,415,000 (New Position) |
Filing History |
| 2024-09-20 4:21 pm Purchase |
2024-09-12 | 13G | Fulcrum Therapeutics, Inc. FULC |
TCG Crossover GP II, LLC | 5,000,000 9.400% |
5,000,000 (New Position) |
Filing History |
| 2024-08-26 6:49 pm Purchase |
2024-08-14 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
TCG Crossover GP II, LLC | 4,643,812 6.800% |
4,643,812 (New Position) |
Filing History |
| 2024-03-15 4:18 pm Purchase |
2024-03-06 | 13G | Nektar Therapeutics NKTR |
TCG Crossover GP II, LLC | 20,046,350 9.900% |
20,046,350 (New Position) |
Filing History |
| 2024-02-15 4:20 pm Purchase |
2024-02-12 | 13G | Mineralys Therapeutics, Inc. MLYS |
TCG Crossover GP II, LLC | 3,185,185 6.400% |
3,185,185 (New Position) |
Filing History |
| 2024-02-15 4:17 pm Purchase |
2024-02-08 | 13G | Adverum Biotechnologies, Inc. ADVM |
TCG Crossover GP II, LLC | 2,076,357 9.900% |
2,076,357 (New Position) |
Filing History |
| 2024-01-16 4:18 pm Purchase |
2024-01-05 | 13G | Astria Therapeutics, Inc. ATXS |
TCG Crossover GP II, LLC | 4,368,928 9.900% |
4,368,928 (New Position) |
Filing History |
| 2023-10-16 4:37 pm Purchase |
2023-10-04 | 13G | VistaGen Therapeutics, Inc. VTGN |
TCG Crossover GP II, LLC | 2,702,157 9.900% |
2,702,157 (New Position) |
Filing History |